LivaNova LIVN Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $539.71M-15.1% | $635.55M-1.6% | $646.08M+8.8% | $593.64M-19.6% | $738.44M+2.1% | ||
| $229.27M+6.2% | $215.99M+2.1% | $211.58M-3.9% | $220.2M+9.0% | $202.08M+4.6% | ||
| $165.5M+0.5% | $164.7M-1.7% | $167.54M+1.3% | $165.35M+7.4% | $154.02M+4.4% | ||
| $1.01B-7.9% | $1.1B+0.4% | $1.1B+2.9% | $1.07B-9.0% | $1.17B+3.9% | ||
| $255.48M+5.3% | $242.6M+11.0% | $218.51M+11.8% | $195.42M+10.0% | $177.68M+4.4% | ||
| $785.59M-0.9% | $792.84M+0.2% | $791.03M-0.3% | $793.37M+4.1% | $761.91M+1.6% | ||
| $224.56M-2.4% | $229.96M-1.9% | $234.53M-1.9% | $239.14M+1.1% | $236.59M-0.3% | ||
| $2.52B-3.4% | $2.61B+1.9% | $2.56B+2.0% | $2.51B-2.0% | $2.56B+2.1% | ||
| $99.15M+2.0% | $97.16M+10.2% | $88.16M+1.4% | $86.93M-0.8% | $87.64M+25.7% | ||
| $16.2M+40.7% | $11.51M+3.8% | $11.08M-0.8% | $11.18M-2.4% | $11.45M+5.5% | ||
| $121K-99.6% | $30.88M-63.9% | $85.42M+4.0% | $82.1M+4.0% | $78.93M+2.1% | ||
| $762.48M-5.6% | $808.07M-2.4% | $827.59M+0.1% | $827.1M+11.5% | $741.57M+89.1% | ||
| $285.16M-17.4% | $345.19M-1.1% | $349.03M+0.2% | $348.49M-36.5% | $549.22M-0.1% | ||
| $196.6M+11.7% | $176.08M-87.4% | $1.4B+1.2% | $1.38B-9.2% | $1.52B+28.5% | ||
| $84.56M0.0% | $84.56M+0.1% | $84.52M0.0% | $84.52M+0.1% | $84.45M+1.6% | ||
| -$1.12B+1.9% | -$1.15B+2.6% | -$1.18B+2.2% | -$1.2B+2.2% | -$1.23B-36.2% | ||
| $1.21B+0.9% | $1.2B+3.7% | $1.16B+3.1% | $1.12B+8.6% | $1.03B-21.7% | ||
| $2.52B-3.4% | $2.61B+1.9% | $2.56B+2.0% | $2.51B-2.0% | $2.56B+2.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can LivaNova cover its short-term obligations?
- Its current ratio is 1.33 — current assets exceed current liabilities.
- Where does LivaNova's balance sheet data come from?
- Every line is extracted from LivaNova's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.